Dr. GPCR

Stronger pharmacology drives smarter decisions in GPCR discovery. Terry’s Corner is now live—an on-demand learning hub led by Dr. Terry Kenakin. Whether you’re refining assay strategy or evaluating data, these lessons give you the tools to think clearer and act faster.

♦️ 10 concise lessons + new weekly content

♦️ Short videos, crisp takeaways, and handpicked references

♦️ Built for GPCR scientists and decision-makers

Also in this week’s Dr. GPCR Weekly:

♦️ Yamina’s Corner—GPCR consulting to de-risk and accelerate your pipeline

♦️ Celtarys’ validated TR-FRET assay for CB1/CB2

♦️ Chemokine-GPCR selectivity decoded

♦️ PTH1R structures reveal Gq bias mechanisms

♦️ NMBR simulations uncover new activation pathways

♦️ Axcelead & Superluminal expand collaboration

♦️ Industry momentum: collaborations, new data, and next-gen GLP-1 strategies

Unlock deeper insight—starting now.

➡️ Read the newsletter: https://buff.ly/lca0KCU

Terry's Corner is Officially LIVE! 🎉

This is your new go-to for mastering drug discovery pharmacology. No fluff, just clear, on-demand insights from Dr. Terry Kenakin.

Building core expertise? Master dose-response, binding, kinetics, and foundational models.

Driving drug discovery? Apply pharmacology to selectivity, ADME, and strategic decision-making.

An experienced drug hunter? Sharpen your edge with allosteric bias, residence time, and translational PK/PD.

Learn on-demand, apply immediately: https://buff.ly/OYnprcC

Some biotech stories start in the lab. Celtarys started with a thesis project, a new chemical strategy, and a vision to make fluorescence available for drug discovery. Now, they’re growing fast and partnering with Dr. GPCR to connect with the researchers who need them most.

✳️ Learn more about the partnership: https://buff.ly/7Hb37Jt

From receptor theory to real-world assays—GPCR innovation is scaling up.

Terry’s Corner is launching soon to deliver decades of pharmacological expertise, while Celtarys shares powerful assay strategies and the leadership behind them.

♦️ Novo’s amycretin hits 24% weight loss; semaglutide patent opens new doors
♦️ CXCR4 nuclear signaling guides red blood cell maturation
♦️ CXCL13/CXCR5 and biased 5-HT1A are emerging pain targets

Explore this week’s GPCR breakthroughs
https://buff.ly/xkl2FtJ

What if β-arrestin recruitment doesn’t follow the same rules across a receptor family?

A new study in the Journal of Proteome Research (Lamb et al., 2025) used mass spectrometry to map phosphorylation in GLP‑1R, GCGR, and GIPR—revealing distinct rules for β-arrestin engagement.

♦️ GLP‑1R and GIPR require phosphorylation for β-arrestin recruitment
♦️ GCGR engages β-arrestins independently of phosphorylation
♦️ Highlights receptor-specific phospho-barcodes within class B1 GPCRs

This study refines our models of biased signaling and offers a clearer path to selective drug design.

📖 Differential Role of Phosphorylation in Glucagon Family Receptor Signaling Revealed by Mass Spectrometry
Ian M. Lamb, Alex D. White, Francis S. Willard, Michael J. Chalmers, Junpeng Xiao
Journal of Proteome Research, 2025
https://buff.ly/2F0oO5c